Accuracy of a New Algorithm to Identify Asthma-COPD Overlap (ACO) Patients in a Cohort of Patients with Chronic Obstructive Airway Disease
Arch Bronconeumol (Engl Ed). 2018 Apr;54(4):198-204.
doi: 10.1016/j.arbres.2017.10.007.
Epub 2017 Dec 9.
[Article in
English,
Spanish]
Affiliations
- 1 Department of Respiratory Medicine, Hospital Lucus Augusti, Lugo, Spain. Electronic address: eremos26@hotmail.com.
- 2 Department of Respiratory Medicine, Hospital Universitario Son Espases-IdISBa, Palma de Mallorca, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
- 3 CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain; Department of Respiratory Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
- 4 CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain; Department of Respiratory Medicine, Hospital de la Santa Creu y Sant Pau, Institut d'Investigació Biomédica Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Department of Medicine, Barcelona, Spain.
Abstract
Objectives:
We aimed to characterize the clinical, functional and inflammatory features of patients diagnosed diagnosed with ACO according to a new algorithm and to compare them with those of other chronic obstructive airway disease (COAD) categories (asthma and COPD).
Methods:
ACO was diagnosed in a cohort of COAD patients in those patients with COPD who were either diagnosed with current asthma or showed significant blood eosinophilia (≥300cells/μl) and/or a very positive bronchodilator response (>400ml and >15% in FEV1).
Results:
Eighty-seven (29.8%) out of 292 patients fulfilled the ACO diagnostic criteria (12.8% asthmatics who smoked <20 pack-years, 100% of asthmatics who smoked ≥20 pack-years, 47.7% of COPD with >200eosinophils/μl in blood and none with non-eosinophilic COPD). ACO, asthma and COPD patients showed no differences in symptoms or exacerbation rate. Mean pre-bronchodilator FEV1 in ACO and asthma were similar (1741 vs 1771ml), higher than in COPD (1431ml, p<0.05). DLCO was lower in ACO than in asthma (68.1 vs 84.1%) and similar to COPD (64.5%). Mean blood eosinophil count was similar in ACO and asthma (360 vs 305cells/μl) and higher than in COPD (170cells/μl). Periostin levels were similar in ACO to COPD (36.6 and 36.5IU/ml) and lower than in asthma (41.5IU/ml, p<0.05), whereas FeNO levels in ACO were intermediate.
Conclusion:
This algorithm classifies as ACO all smoking asthmatics with non-fully reversible airway obstruction and a considerable proportion of e-COPD patients, highlighting those who can benefit from inhaled corticosteroids.
Keywords:
Asma; Asthma; Asthma-chronic obstructive pulmonary disease overlap; Chronic obstructive pulmonary disease; Enfermedad pulmonar obstructiva crónica; Superposición asma-Enfermedad pulmonar obstructiva crónica.
Copyright © 2017 SEPAR. Publicado por Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Adrenal Cortex Hormones / therapeutic use
-
Airway Obstruction / etiology
-
Algorithms*
-
Anti-Asthmatic Agents / therapeutic use
-
Asthma / complications*
-
Asthma / diagnosis
-
Asthma / epidemiology
-
Asthma / physiopathology
-
Breath Tests
-
Bronchodilator Agents / therapeutic use
-
Cell Adhesion Molecules / blood
-
Comorbidity
-
Drug Therapy, Combination
-
Eosinophilia / epidemiology
-
Forced Expiratory Volume
-
Humans
-
Inflammation
-
Nitric Oxide / analysis
-
Pulmonary Disease, Chronic Obstructive / complications*
-
Pulmonary Disease, Chronic Obstructive / diagnosis
-
Pulmonary Disease, Chronic Obstructive / epidemiology
-
Pulmonary Disease, Chronic Obstructive / physiopathology
-
Smoking / epidemiology
Substances
-
Adrenal Cortex Hormones
-
Anti-Asthmatic Agents
-
Bronchodilator Agents
-
Cell Adhesion Molecules
-
POSTN protein, human
-
Nitric Oxide